Creative Bioarray
  • USA:
  • Europe:
LOGO
  • Home
    • About Us
    • Contact Us
    • Events
  • Screening
    • Ionic Screening Service
      • Ion Flux Assay
      • Fluorescence Assay
      • Patch-clamp Assay
    • Ionic Screening Panel
      • Sodium Channels
      • Potassium Channels
      • Chloride Channels
      • Calcium Channels
      • TRP Channels
      • ATP gated P2X Channels
      • ASICs
      • Nicotinic Acetylcholine Receptors
      • Ionotropic Glutamate-gated Receptors
      • GABAa Receptors
      • Glycine Receptors
      • 5-HT Receptors3
      • Cystic Fibrosis Transmembrane Conductance Regulators (CFTR)
      • Other Ion Channels
    • Stable Cell Lines
      • Ion Channel Expressing Cell
      • GPCR Expressing Cell
      • Other Membrane Receptors/Transporters/Exchangers Expression Cell
      • Customized Ionic Channel Expression System
  • Cardiology
    • Cardiac Ion Channel Screen Panels
      • HERG (IKR, KV11.1)
      • Cav1.2
      • Kv4.3
      • KCNQ1/mink/Kv7.1
      • Kir2.1
      • Nav1.5
      • Kv1.5
      • HCN1&HCN4
      • Other Ion Channels
    • CiPA
      • CiPA Cardiac Channel Assays
      • CiPA In silico Modeling
      • CiPA Translational Assays
    • 3D Cardiotoxicity
    • Cardiomyocyte Functions
      • Action Potential Properties
      • Calcium Transient in Cardiomyocytes
      • QT Service Using Langendorff Perfused Heart
    • Cardiac in vivo Assays
      • QRS, QT Waves Detection by ECG
  • Neurology
    • Neurotransmission Functions
      • sEPSC/sIPSC Recordings
      • fEPSP / Populational Spikes Recordings
      • LTP & LTD Formation or Deficit Detection
    • Basic Neuronal Activity
      • Action Potential Properties Assay
      • NMDA/AMPA Ratio Test
      • Calcium Signaling Test
      • Customized Electrophysiological Test
    • Neuronal in vivo Assays
      • In vivo Extra-cellular Recordings/Whole-cell Patch-clamp Recordings
      • Continuous Telemetric EEG Recordings
    • Animal Behavior Tests
      • Spontaneous Locomotor Functions
      • Cognitive Functions
      • Anxiety-Depression and Social Interaction Evaluation
      • Assays for Neuropsychiatric Disorders
  • Ophthalmology
  • Platform
    • Experiment Systems
      • Xenopus Oocyte Screening Model
      • Acute Isolated Cardiomyocytes
      • Acute Dissociated Neurons
      • Primary Cultured Neurons
      • Cultured Neuronal Cell Lines
      • iPSC-derived Cardiomyocytes/Neurons
      • Acute/Cultured Organotypic Brain Slices
      • Oxygen Glucose Deprivation Model
      • 3D Cell Culture
      • iPSC-derived Neurons
      • Isolation and culture of neural stem/progenitor cells
    • Animal Models
      • Alzheimer's Disease Model
      • Parkinson's Disease Model
      • Huntington's Disease Model
      • Epilepsy Model
      • ALS Model
      • Psychiatric Model
      • Autism Spectrum Disorder
      • Cerebral-Spinal Injury Model
      • Pain Model
      • Stroke Model
      • Fragile X Model
      • Acute/Chronic Heart Failure Model
    • Techinques
      • Manual Patch-clamp Technique
      • Automated Patch-clamp
      • Multi-Electrode Array (MEA)
      • FluxOR™ Thallium Assay
      • FLIPR Detection System
      • Optogenetics
      • Neuronal Tract Tracing
    • Resource
      • Technical Methods
      • Neuroscience
      • Channelopathies
      • Channelomics
    • Equipment
  • Order
  • Careers
  • Home
  • Cardiology
  • Cardiac in vivo Assays
  • Screening
  • Ionic Screening Service Ionic Screening Panel Stable Cell Lines
  • Cardiology
  • CiPA 3D Cardiotoxicity Cardiomyocyte Functions Cardiac in vivo Assays Cardiac Ion Channel Screen Panels
  • Neurology
  • Basic Neuronal Activity Neurotransmission Functions Neuronal in vivo Assays Animal Behavior Tests
  • Platform
  • Experiment Systems Animal Models Techinques Resource Equipment

Cardiac in vivo Assays

In cardiac safety studies, hERG testing is positioned early such that lead structures are evaluated prior to entering lead optimization for hERG-blocking potential. Lead optimization programs are supported with additional studies to examine the myocardial action potential and manual patch-clamping studies to determine IC50 values for hERG blockade for interesting candidates.


2-5 Cardiac in vivo assays-1.jpg


In vivo studies are done toward the end of the lead optimization process on selected candidates for final characterization and selection. GLP studies are done only for development compounds being prepared for clinical trials. Creative Bioarray has conducted in vivo testing for cardiovascular disease using in vivo models for both side-effect profiling and efficacy according to your requirement.


2-5 Cardiac in vivo assays-2.jpg

Fig. 1 Depiction of the timing of various safety pharmacology studies for cardiovascular liabilities


Creative Bioarray provides a variety of study endpoints to generate the high-quality, reproducible data according to your research program requirement. All test models are analyzed in a dose-dependent manner with approved benchmark positive controls. Each of our technical directors specializes in selected research areas so they will provide expert scientific support to you. They are involved in all process including consulting with you to identify an appropriate model to meet scientific objectives, designing studies and writing protocols and statements of work (SOWs) to meet the quality assurance guidelines. They also work closely with our study directors to assure that SOWs are clear and that all methods and timelines are feasible. To meet the needs of your specific Cardiovascular drug discovery project we also have the flexibility and expertise to develop custom in vivo models.

We provide protocols including screening study designs for preliminary safety assessment, ECG/MAP/LVP, Coronary flow/pressure, MAP duration, QT & QRS duration, LVDP, MAP triangulation (instability), frequency-dependence & restitution, effective refractory period. Whether you are trying to evaluate potential cardiovascular liabilities during lead optimization or trying to verify in vivo efficacy, we can provide high quality and reproducible results to progress your drug discovery program.

Highlights

  • Both GLP compliant studies for IND submission and non GLP compliant studies available

  • Multiple Species

  • Telemetry (Invasive and Non-Invasive; ECG and systemic/ventricular pressures)

  • Cardiac Output and Chronic Load-Independent Cardiac Function

  • Imaging (Echocardiography, CT, MRI, x-ray)

Applications

  • QRS,QT waves Detection by Electrocardiogram

    Heart Rate (HR, bpm)

    PR interval (ms)

    QRS interval (ms)

    QT and corrected QT

  • Cardiac Activity Evaluation

    Ejection fraction

    Heart Structure

    Basic Cardiovascular Functions

    Arterial Blood Pressure (ABP, mmHg)

    Left Ventricular Pressure (mmHg)

  • Customized Services

Quotation and Ordering

If you have any special needs in our Cardiac in vivo Assay Service, please contact us at Email or Telephone for this special service. Let us know what you need and we will accommodate you. We look forward to working with you in the future.

Reference

  1. Guth, B. D. Preclinical cardiovascular risk assessment in modern drug development. Toxicol Sci. 2007; 97: 4–20.


For research use only.

Related Section

  • Cardiac Ion Channel Screen Panels
  • CiPA
  • 3D Cardiotoxicity
  • Cardiomyocyte Functions

Inquiry


Subscribe
  • Links
  • Sodium Channels
  • Calcium Channels
  • Potassium Channels
  • Chloride Channels
  • TRP Channels
  • ATP gated P2X Channels
  • ASICs
  • USA
  • Europe

Copyright © 2025 Creative Bioarray. All rights reserved.